Scientific Report 2016
Headquarters
C/ Muntaner, 383 3r. 08021 Barcelona
Tel. (+34) 93 414 55 66

For any matter concerning this report please contact:
comunicacio@carrerasresearch.org
The report can also be downloaded from: http://www.carrerasresearch.org

Publisher, layout and typesetting
Josep Carreras Leukaemia Research Institute

Photography
Photographic archives of the Josep Carreras Leukaemia Foundation and the Josep Carreras Leukaemia Research Institute
“The Institute’s three campuses are surrounded by excellent scientific and health service facilities. It is the aim of our project to enhance, integrate, share and strengthen this already excellent situation even more, and this is already being done at the management level, by simplifying and sharing structures, and at the scientific level, by integrating cross-section and multi-site services to avoid unnecessary duplication. Everything we do is focused on making leukaemia and other malignant blood diseases 100% curable one day.”

Josep Carreras
President of the Board of Trustees
Josep Carreras Leukaemia Research Institute (IJC)
Contents
About us
Welcome

Behind all research there is a patient, a relation, a person, a team, a community, a hospital, a research centre, an organisation, a patron…

Together we are unstoppable against leukaemia!

Once again the IJC’s annual report is testimony to the excellent research being carried out at the three Josep Carreras campuses. Our congratulations are due, therefore, to everyone for their magnificent work and scientific rigour.

2016 was a year in which progress was made in the fight against leukaemia. It was a year of combined scientific efforts, continuing cooperation and commitment to society.

And our centre has seen the expansion of its facilities come true with the opening of the new building in Badalona, made possible by funding from the Josep Carreras Foundation.

Notable aspects of the IJC’s management and leadership were the approval of the integrating SUMA project between the Germans Trias Institute (IGTP) and the Institute for Predictive and Personalised Cancer Medicine (IMPPC), the incorporation of new research groups, and the acquisition of new technological equipment.

Similarly notable has been the ability to synchronise research, health care, innovation and teaching, something of fundamental importance for achieving scientific excellence.

With all this in mind, it is our pleasure to invite you to learn more from the following pages about the activities in 2016, activities which have earned this centre a leading position in biomedical research to confront leukaemia.

Evarist Feliu
President of the Delegate Committee of the Josep Carreras Leukaemia Research Institute
Who we are

Three campuses united to win the battle against leukaemia and other malignant blood diseases

The Josep Carreras Leukaemia Research Institute (IJC), a Generalitat de Catalunya Research Centre (CERCA), was established with the aim of promoting biomedical research into, and the development of, personalised medicine in the field of malignant blood diseases, especially leukaemia. It is a centre without precedent which, with the work and dedication of researchers from around the world, uses the most innovative technologies to try to vanquish leukaemia and other malignant blood diseases.

The IJC has three independent and coordinated scientific campuses: the Hospital Clinic-UB Campus, located at the research facilities of Barcelona's Hospital Clinic, and those of the University of Barcelona (UB) Faculty of Medicine, coordinated by Dr. Álvaro Urbano Ispizua, under the research direction of Dr. Pablo Menéndez; the Catalan Institute of Oncology/Germans Trias i Pujol Campus in Badalona, located near the Germans Trias i Pujol University Hospital and its research foundation and the Autonomous University of Barcelona (UAB) Germans Trias i Pujol Teaching Unit. The ICO-Germans Trias i Pujol Campus is coordinated by Dr. Evarist Feliu and the Research Director is Dr. Francesc Solé. The third campus is the Sant Pau Campus and its research foundation, located within the health care facilities of the Hospital de la Santa Creu i Sant Pau and the UAB's Sant Pau teaching unit, coordinated by Dr. Jordi Sierra.

The IJC's Hospital Clinic-UB Campus reaffirms the UB Faculty of Medicine and the Hospital Clinic's scientific commitment to excellence in the field of hematology, which commenced with the work of Prof. Farreras Valentí and which has been able to continue thanks to the extraordinary work carried out by Prof. Ciril Rozman and those who studied under him.
Mission

The Josep Carreras Leukaemia Research Institute's mission is to carry out research into the basic, epidemiological, preventive, clinical and transferable aspects of leukaemia and other malignant blood diseases in order to find a cure for them.

Vision

The Josep Carreras Leukaemia Research Institute's vision is to be a world-renowned, multi-campus research centre of excellence that contributes towards improved outcomes and a cure for leukaemia and other malignant blood diseases through innovation, sustainability, social responsibility, talent and professional expertise.

Values

Altruism and example-setting, in accordance with the Foundation's principles.

Patient-orientated, proximity.

Staff commitment and correlation.

Mutual respect.

Corporate alignment of the 3 campuses and the Foundation.

Participative and shared leadership.

Continuing cooperation agreements and the forging of alliances.

The integration of research and health care.

Continuous improvement and perseverance as guiding principles.

Conceptual, methodological and technological innovation.

Sustainable management.

Procedural efficacy.

Efficiency in the optimisation of resources.

Transparency, public dissemination and openness.

Continuous evaluation and accountability.
Our team
Governing Bodies

The highest governing body is the Board of Trustees, on which are represented: the Josep Carreras Foundation, the Catalan Government Ministry of Business and Knowledge, the Catalan Government Ministry of Health, the Autonomous University of Barcelona (UAB), the University of Barcelona (UB), Badalona Town Council, the Directorate General for Health Research and Planning, the Catalan Institute of Oncology, the Northern Metropolitan Territorial Area Administration, the Catalan Foundation for Research and Innovation, the Hospital Clinic/August Pi i Sunyer Institute for Biomedical Research (Idibaps), the UB Hospital Coordination Committee and the Research Centres of Catalonia Institution Foundation (iCERCA).

Board of Trustees

President
Mr. Josep Carreras Coll  President of the Josep Carreras Leukaemia Research Institute

First Vice-president
Mr. Jordi Baiget i Cantons  Catalan Government Minister of Business and Knowledge

Second Vice-president
Mr. Antoni Comín i Oliveras  Catalan Government Minister of Health

Members
Margarita Arboix Arzo  Rector Autonomous University of Barcelona (UAB)
Joan Elias Garcia  Rector University of Barcelona (UB)
Maria Dolors Sabater i Puig  Mayor of Badalona

Francesc Subirada i Curcó  Director General for Research, Catalan Government Ministry of Business and Knowledge
Antoni Andreu Pérez  Director General for Health Research and Planning
Montserrat Llavayol i Giralt  Deputy Director General for Health Research and Planning
Candela Calle Rodríguez  Director General Catalan Institute of Oncology
Jordi Ara del Rey  Administrator Northern Metropolitan Territorial Area
Arcadi Navarro Cuartielles  Secretary for Universities and Research, Catalan Government Ministry of Business and Knowledge
Rafael Marin Gálvez  Director Catalan Foundation for Research and Innovation
Elias Campo Güerri  Research Director Hospital Clinic - IDIBAPS
Albert Carreras Coll  Treasurer of the Josep Carreras Leukaemia Foundation
Ciri Rozman Borstnar  Former Vice-president of the Josep Carreras Leukaemia Foundation
Evarist Feliu Frasnedo  Vice-president of the Josep Carreras Leukaemia Foundation
Antoni García Prat  Administrator of the Josep Carreras Leukaemia Foundation
Armand Sanchez Bonastre  Vice-rector for Research and Transferability, Autonomous University of Barcelona (UAB)
César Picado Vallés  University of Barcelona Hospital Coordination Committee

Secretary
Lluís Rovira Pato  Director of the Research Centres of Catalonia Institution Foundation (iCERCA)
Delegate Committee

President
Prof. Evarist Feliu,
Coordinator of the ICO-Germans Trias i Pujol Campus

Members
Francesc Subirada i Curcó
Director General for Research, Catalan Government Ministry of Business and Knowledge
Dr. Antoni Andreu Pérez
Director general for health research and innovation
David Elvira i Martínez
Director of the Catalan Health Service
Jaume Raventós
Director of the Catalan Research Service
Dr. Lluis Rovira Pato
Director iCerca, CERCA Institution, Research Centers of Catalonia
Mr. Antoni Garcia Prat
Administrator, Josep Carreras International Foundation
Dr César Picado Vallés
University of Barcelona Hospital Coordination Committee Chairman
Dr. Lluis Tort Bardolet
Vice-rector for Strategic Projects and Planning, Autonomous University of Barcelona

External Scientific Committee

President
Prof. Lucio Luzzatto, Nigerian Haematology Association

Members
Prof. Robert Sackstein, Dana-Farber/Harvard Cancer Center Boston
Prof. Francesco Lococo, Università degli Studi di Roma "Tor Vergata"
Prof. Alberto Orfao, CIC Centro de Investigación del Cáncer Salamanca
Prof. Brigitte Schlegelberger, University of Hannover

Internal Scientific Committee

UB-Clínic Campus
Álvaro Urbano Ispizúa (Internal Scientific Committee Coordinator)
Pablo Menéndez (Campus Research Director)
Jordi Esteve Reyner
Armando López Guillermo
Joan Bladé Creixentí
Francisco Cervantes Requena

ICO-GTIP Campus
Evarist Feliu Frasnedo (President of the Delegate Committee)
Francesc Solé (Campus Research Director)
Josep Mª Ribera Santasusana
Lurdes Zamora Plana
José Tomás Navarro Ferrando
Juan Manuel Sancho Cía

Sant Pau Campus
Jordi Sierra
Josep Nomdedeu
Joan Carles Souto
Ramon Mangues
Carol Moreno
Organisational chart

Scientific Directors

ICO-GTP Campus
Francesc Solé

Clinic-UB Campus
Pablo Menéndez

Sant Pau Campus
Jordi Sierra
Human resources

IJC Germans Trias

Linked with IJC

Aranda Cebrian, Jessica
Barque Falquera, Anna
Batista, Lopes
Buschbeck, Marcus
Cid Roldos, Emili
Corujo Garcia, David
Couso de la Torre, Jorge
de Haro Camps, Núria
Diesch, Jeannine
Douet Julien, Thierry
Estrada Barreras, Natalia
Fita Torro, Josep
Fuster Torno, Francisco
Garcia Calduch, Olga
Garcia Rico, Laura
Genesca Ferrer, Eulalia
Gomes Monteiro, Maria Joao
Gomez Marzo, Paula
Guberovic, Iva
Hurtado, Sarah
Ibarra Fernandez, Gladys
Llobet Reixach, Laura
Maher, Michael
Malinvernì, Roberto
Mallo Fajula, Maria del Mar
Muncunill Farreny, Josep
Palomo Sanchis, Laura
Pasquali, Lorenzo
Petriz Gonzalez, Jorge Mario
Ribera Salas, Jordi
Ruiz Cortes, Rocío
Sanchez Fernandez, M Carmen
Solanes Hernandez, Neus
Sole Ristol, Francesc
Valero Lazaro, Vanesa
Vavouri, Soultana
Vidal Santorum, Adria
Yamamoto, Fumihiro
Yamamoto, Miyako

IJC Clínica

Linked with IJC

Agraz Doblas, Antonio Manuel
Banus Mulet, Antonia
Bueno Uroz, Clara
Castaño Cardoso, Julio
Cobo Sanchez, Isabel
Diaz de la Guar Quiles, Rafael
Dominguez Mohedano, Sonia
Etxabe Alberdi, Amaia
Fernandez Martin, Adrian
Gutierrez Valle, Victoria
Krisheevskaya, Elena
Libero Baroni, Matteo
Llaudet Planas, Esther
Lopez Millan, Belen
Mañu Pereira, Maria del Mar
Masso Chacon, Anna
Menendez Bujan, Pablo
Mir Fuertes, Enrique
Molina Campoy, Oscar
Muñoz Risueño, Ruth
Palomo de Udaeta, Marta
Prieto Fernandez, Cristina
Rizzutto, Valeria
Roca Ho, Heleia
Rodriguez Cortez, Virginia
Suñe Rodriguez, Guillermo
Torres Ruiz, Raul

IJC Sant Pau

Linked with IJC

Aljarilla Medina, Alba
Esquirol Sanfeliu, Albert
Millon Cano, Juan Antonio
Virgin Alamo Vargas, Patricia
Linked with hospital

Batlle, Montse. Post doc
Cabezon, Marta. Post doc
Cisneros, Adela. Pre doc
Feliu, Evarist. Director
Ferra, Christelle. LR
Granada, Isabel. Post doc
Grau, Javier. Post doc
Junca, Jordi. Post doc
Marce, Silvia. Post doc
Milla, Fuensanta. Post doc
Navarro, Tomáš. LR
Oriol, Albert. LR
Ribera, Josep Maria. LR
Rodríguez, Inés. Pre doc
Ruiz, Neus. Pre doc
Sancho, Juanma. LR
Vives, Susana. Pre doc
Xandri, Marisol. Pre doc
Xicoy, Blanca. LR
Zamora, Lurdés. LR

Linked with hospital

Blade, Joan. LR
Esteve, Jordi. LR
Larrea, Carlos. Post doc
Urbano, Alvaro. Director

Linked with hospital

Barata, Ana. Post doc
Briones, Javier. LR
Mangues, Ramon. LR
Moreno, Carol. LR
Nomdedeu, Josep. LR
Pratcorona, Marta. Post doc
Sierra, Jordi. Director
<table>
<thead>
<tr>
<th>Category</th>
<th>IJC ICO</th>
<th>IJC Clinic UB</th>
<th>IJC Sant Pau UAB</th>
<th>IJC Shared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead researchers</td>
<td>7</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-doctoral researchers</td>
<td>14</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-doctoral researchers</td>
<td>7</td>
<td>7</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Support staff</td>
<td>10</td>
<td>8</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Management and administration</td>
<td>1</td>
<td></td>
<td></td>
<td>25</td>
</tr>
<tr>
<td>Staff professionally linked</td>
<td>39</td>
<td>27</td>
<td>4</td>
<td>25</td>
</tr>
<tr>
<td>Staff professionally linked</td>
<td>30</td>
<td>15</td>
<td>19</td>
<td></td>
</tr>
</tbody>
</table>

**Staff professionally linked with the IJC**:
- Germans Trias UAB: 56%
- Clinic UB: 38%
- Sant Pau UAB: 6%
At the three hospitals where the IJC has a presence there has always been a great willingness to participate in clinical research. And there are clinics with a very considerable background in basic sciences. Integration, in this respect, must therefore not be just a question of maintaining present levels, but of increasing them in order to enhance the added value it represents in both the health sciences and in clinical practice.
Financial data
In 2016 there was an increase of more than 7% in income from the capture of public funds and the provision of services. With regard to expenses, 60% of the IJC's outlay corresponds to staffing, with an increase of 14%. At this early stage the evolution of income, expenses and investments gives a negative result of €472,531.22.

<table>
<thead>
<tr>
<th>Income from activities</th>
<th>€3,603,917.96</th>
</tr>
</thead>
<tbody>
<tr>
<td>Services rendered</td>
<td>€591,733.98</td>
</tr>
<tr>
<td>Official subsidies for activities</td>
<td>€2,356,251.98</td>
</tr>
<tr>
<td>Other subsidies, donations…</td>
<td>€655,932.00</td>
</tr>
<tr>
<td>Self-constructed assets</td>
<td>€10,517.60</td>
</tr>
<tr>
<td>Supplies</td>
<td>- €860,955.55</td>
</tr>
<tr>
<td>Other income from activity</td>
<td>€20,404.62</td>
</tr>
<tr>
<td>Staff costs</td>
<td>- €2,149,326.75</td>
</tr>
<tr>
<td>Wages and salaries</td>
<td>- €1,686,478.26</td>
</tr>
<tr>
<td>Social security expenses</td>
<td>- €462,848.49</td>
</tr>
<tr>
<td>Other expenses</td>
<td>- €605,889.15</td>
</tr>
<tr>
<td>External services</td>
<td>- €591,785.93</td>
</tr>
<tr>
<td>Taxes</td>
<td>- €474.83</td>
</tr>
<tr>
<td>Losses, depreciation…</td>
<td>- €10,517.60</td>
</tr>
<tr>
<td>Other current period losses</td>
<td>- €3,110.79</td>
</tr>
<tr>
<td>Fixed asset depreciation</td>
<td>- €525,869.73</td>
</tr>
<tr>
<td>IJC Subsidy</td>
<td>€53,338.50</td>
</tr>
<tr>
<td>Other income</td>
<td>€1,938.20</td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>- €451,924.30</td>
</tr>
<tr>
<td>Financial income</td>
<td>€208.24</td>
</tr>
<tr>
<td>Financial expenses</td>
<td>- €19,940.62</td>
</tr>
<tr>
<td>Subsidy return expenses</td>
<td>- €379.47</td>
</tr>
<tr>
<td>Exchange rate differences</td>
<td>- €874.54</td>
</tr>
<tr>
<td>Financial result</td>
<td>- €20,606.92</td>
</tr>
<tr>
<td>Surplus / deficit before tax</td>
<td>- €472,531.22</td>
</tr>
<tr>
<td>Tax on profit</td>
<td>-</td>
</tr>
<tr>
<td>SURPLUS / DEFICIT OF THE FINANCIAL YEAR</td>
<td>- €472,531.22</td>
</tr>
</tbody>
</table>
Balance sheet

<table>
<thead>
<tr>
<th>ASSETS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-current assets</strong></td>
<td>€13,671,488.67</td>
</tr>
<tr>
<td>Intangible fixed assets</td>
<td>€2,062,459.46</td>
</tr>
<tr>
<td>Tangible fixed assets</td>
<td>€11,576,049.93</td>
</tr>
<tr>
<td>Long-term investments in group and associated entities</td>
<td>€2,000.00</td>
</tr>
<tr>
<td>Long-term financial investments</td>
<td>€30,979.28</td>
</tr>
<tr>
<td><strong>Current assets</strong></td>
<td>€5,860,833.65</td>
</tr>
<tr>
<td>Stock</td>
<td>€14,879.00</td>
</tr>
<tr>
<td>Users, sponsors and other debtors from activities</td>
<td>€5,716,590.75</td>
</tr>
<tr>
<td>Other credits with the public administration</td>
<td>-</td>
</tr>
<tr>
<td>Short-term financial investments</td>
<td>-</td>
</tr>
<tr>
<td>Short-term accruals</td>
<td>€18,168.09</td>
</tr>
<tr>
<td>Cash and others</td>
<td>€111,195.81</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td>€19,532,322.32</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net assets</strong></td>
<td>€11,478,998.01</td>
</tr>
<tr>
<td>Equity</td>
<td>€10,269,001.97</td>
</tr>
<tr>
<td>Start-up funds</td>
<td>€11,660,719.37</td>
</tr>
<tr>
<td>Special funds</td>
<td></td>
</tr>
<tr>
<td>Profit or loss from previous years</td>
<td>- €919,186.18</td>
</tr>
<tr>
<td>Year profit or loss</td>
<td>- €472,531.22</td>
</tr>
<tr>
<td>Subsidies, donations and legacies</td>
<td>€1,209,996.04</td>
</tr>
<tr>
<td><strong>Non-current liabilities</strong></td>
<td>€3,616,843.21</td>
</tr>
<tr>
<td>Long-term debt</td>
<td>€3,616,843.21</td>
</tr>
<tr>
<td><strong>Current liabilities</strong></td>
<td>€4,436,481.10</td>
</tr>
<tr>
<td>Short-term provisions</td>
<td>€10,517.60</td>
</tr>
<tr>
<td>Short-term debt</td>
<td>€2,359,223.16</td>
</tr>
<tr>
<td>Creditors for activities and others</td>
<td>€1,327,251.71</td>
</tr>
<tr>
<td>Short-term debts with group and associated entities</td>
<td>-</td>
</tr>
<tr>
<td>Current tax liabilities and other debts with the public administration</td>
<td>-</td>
</tr>
<tr>
<td>Short-term accruals</td>
<td>€739,488.63</td>
</tr>
<tr>
<td><strong>TOTAL (LIABILITIES + NA)</strong></td>
<td>€19,532,322.32</td>
</tr>
</tbody>
</table>
Evolution of income

- 2012: €502,014.45
- 2013: €1,159,986.81
- 2014: €1,875,004.95
- 2015: €3,378,582.43
- 2016: €3,603,917.96
Scientific activity
Research groups

IJC Germans Trias
- Active projects: 23
- LRs: 7

IJC Clínic
- Active projects: 16
- LRs: 3

IJC Clínic-UB
- Stem Cells
- ALL infant
- AML
- BMT
- NHL
- MM
- MDS

IJC Sant Pau
- Fe and Cancer
- Chromatin
- AML
- NHL
- BMT
- CLL
- Thrombosis and Cancer
- MM
- Animal models: AML, DLBCL
## Competitive funding granted

<table>
<thead>
<tr>
<th>IP</th>
<th>Projects 2016</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcus Buschbeck</td>
<td>BFU MINECO</td>
<td>€201,000,00</td>
</tr>
<tr>
<td>Marcus Buschbeck</td>
<td>ITN H2020</td>
<td>€549,202,86</td>
</tr>
<tr>
<td>Natalia Estrada</td>
<td>FI AGAUR</td>
<td>€45,000,00</td>
</tr>
<tr>
<td>Ruth Muñoz</td>
<td>RETOS COLABORACIÓN MINECO</td>
<td>€181,000,00</td>
</tr>
<tr>
<td>Ruth Muñoz</td>
<td>SAF MINECO</td>
<td>€201,586,00</td>
</tr>
<tr>
<td>Clara Bueno</td>
<td>AECC</td>
<td>€150,000,00</td>
</tr>
<tr>
<td>Jose Mª Ribera</td>
<td>AECC</td>
<td>€487,000,00</td>
</tr>
<tr>
<td>Jose Mª Ribera</td>
<td>IMI</td>
<td>€153,348,00</td>
</tr>
<tr>
<td>Tanya Vavouri</td>
<td>BFU MINECO</td>
<td>€142,000,00</td>
</tr>
<tr>
<td>Mayka Sanchez</td>
<td>Doctorado Industrial</td>
<td>€33,960,00</td>
</tr>
<tr>
<td>Mayka Sanchez</td>
<td>Ramón Areces</td>
<td>€120,000,00</td>
</tr>
<tr>
<td>Mayka Sanchez</td>
<td>RETOS MIENCO</td>
<td>€108,900,00</td>
</tr>
<tr>
<td>Pablo Menendez</td>
<td>RETOS COLABORACIÓN MINECO</td>
<td>€123,562,00</td>
</tr>
<tr>
<td>Raul Torres</td>
<td>LADY TATA</td>
<td>€40,000,00</td>
</tr>
<tr>
<td>Mar Mañu</td>
<td>H2020</td>
<td>€205,766,88</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>€2,742,325,74</strong></td>
</tr>
</tbody>
</table>
Capturing competitive grants

<table>
<thead>
<tr>
<th></th>
<th>ICO Germans UAB</th>
<th>Clinic UB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active projects (national)</td>
<td>19</td>
<td>13</td>
</tr>
<tr>
<td>Projects awarded (national)</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Projects tendered (national)</td>
<td>28</td>
<td>17</td>
</tr>
<tr>
<td>Active projects (international)</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Projects awarded (international)</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Projects tendered (international)</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Projects awarded (public)</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>Projects awarded (private)</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Active research networks</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Competitive funding granted (€)</td>
<td>€1.559.177,00</td>
<td>€1.183.148,00</td>
</tr>
<tr>
<td>Non-competitive funding granted (€)</td>
<td>€512.623,00</td>
<td>€173.000,00</td>
</tr>
<tr>
<td>Sum total competitive and non-competitive overheads granted</td>
<td>€285.379,00</td>
<td>€165.075,00</td>
</tr>
</tbody>
</table>


- Competitive funding granted (€)
- Non-competitive funding granted (€)
Technology platforms

Cytogenetics platform

The Josep Carreras Leukaemia Research Institute cytogenetics platform is directed by Dr. Francesc Solé. The platform includes the Catalan Institute of Oncology's (ICO) Cytogenetics Laboratory and the 32K Bacterial Artificial Chromosome (BAK) library.

Affymetrix Microarrays Platform

The Affymetrix® Microarrays Platform (AMP) is a service focused on microarray DNA and RNA solutions provided by Affymetrix. The main aim is to find solutions, based on basic research, applied research and diagnosis, that lead towards personalised medicine.

Blood cancer samples

The administration of the collection, processing and storage of blood cancer samples. These samples are stored in a collection called 'Collection of samples from patients with hematologic neoplasms'.

Fluidigm Platform

The Fluidigm platform is used to create integrated fluid circuits (IFCs) which are single-use biochips which automate PCR reactions using the volumes of nanolitres from two samples and reagents to produce consistent results.
Clinical trials

Clinical trials are a fundamental part of our research. In this regard, the IJC evaluates treatments, the efficacy of drugs, and the suitability of equipment. It enables new treatments to be tested to prevent, relieve or cure diseases.

The IJC vouches for the transferability of knowledge, and the value of and search for market opportunities, in the broadest terms. As well as being in its own interests, it contributes to society and our country's progress.

At the present time the IJC has the following patent pending:

Methods for treating, diagnosing and prognosing a haematological malignancy.

Inventor: Ruth Muñoz Risueño

WO 2015/197839

PCT/EP2015/064571
Scientific production
Publications

Indexed articles

Global impact factor

Publications 2016

Total articles
99

Total FI articles
99

Accumulated impact factor
797.498

FI 1Q
543.993

Total citations
1,221

Citation index
39.976

Articles 1st quartile
52.11 %
Teaching activities
Teaching

The IJC provides a high-quality teaching programme for students, scientists, technicians and others with an interest in achieving a solid and up-to-date grounding in the field of leukaemia and malignant blood diseases. The IJC organises a Doctorate in Hematology, a Master’s degree in malignant blood diseases and it participates in the teaching for degrees in medicine and biomedicine.

In 2016 the following theses were presented at the IJC:

**Splenic marginal zone lymphoma cytogenetics**
Doctoral student: Cristina Baró (UAB)
Director: Francesc Solé
Barcelona, 1 February 2016

**The Iron Regulatory Protein/Iron Responsive Element (IRP/IRE) system: functional studies of new target mRNAs and pathological implications for novel IRE mutations**
Doctoral student: Sara Luscieti UB
Director: Dr. Mayka Sanchez
22 November 2016

**Polycomb repressive complex 1 functions in differentiation and myelodysplastic syndromes.**
Doctoral student: Anna Palau de Miguel UB
Director: Marcus Buschbech
30 November 2016

Staff linked to the University
7

Theses read
3

Doctorates being prepared
6
Training sessions

The IJC organises complementary training activities at all levels, from scientific conferences, monthly seminars and technology sessions, to specialised courses.

Training courses
5

Scientific conference
1

Scientific seminars
24

MDS GRUP
Francisco Fuster

MPN GROUP
Lurdes Zamora, Blanca Xicoy
Natalia Estrada, Laura Palomo

GLICOLSILATION GROUP
Fumi Yamamoto
Emili Cid

ALL GROUP
JM Ribera
Eulalia Genescà, Jordi Ribera

MYELOMA GROUP
Albert Oriol
Paula Gomez

CLL GROUP
Mª Joao Batista, Christelle Ferra
Maria Joao Baptista

FUNCTIONAL CYTOMICS
Jordi Petriz
Laura Garcia

IRON GROUP
Mayka Sanchez
Jorge Couso, Ana Barque

CHROMATIN GROUP
Marcus Buschbeck
Anna Palau, Sara Alvarez, Jeannine Diesch
Seminars

8 March 2016 at 15.30
Exploring approaches for molecular risk stratification in MDS
Dr. Rafael Bejar. University of California, San Diego (Department of Medicine)
MDS Group Dr. Francesc Solé

21 March 2016 at 15.30
Our experience of a CART19 approach in Barcelona “or” CARs for anti-tumor immunotherapy
Dr. Manel Juan. Hospital Clínica Biomedical Diagnostic Centre (Immunology)
Immunohematology and glicobiology Dr. Fumi Yamamoto

25 April 2016 at 15.30
Novel antigens expressed in Leukemic Stem Cells
Dr. Lidia Campos. Centre Hospitalier Universitaire de Saint Etienne. Head Laboratory Hematologist.
Functional Cytomics Dr. Jordi Pétriz

2 May 2016 at 15.30
Clinical implications of CLL genetics
Dr. Davide Rossi. Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont.
CLL Group Drs. Maria Joao Baptista, Christelle Ferrà and Inés Rodríguez

9 May 2016 at 15.30
Pathophysiological consequences of the disruption of the Hepcidin-Ferroportin regulatory circuitry
Dr. Sandro Altamura. Developmental Biology, Genetics, Molecular Biology MS, PhD.
Universität Heidelberg, Heidelberg
Iron metabolism: regulation and diseases Dr. Mayka Sánchez

23 May 2016 at 15.30
Immunotherapy of lymphoid malignancies with dendritic cells and NKT cell agonists
Dr. Javier Briones. Hospital Sant Pau. Hematology Service
Immunohematology and glicobiology Dr. Fumi Yamamoto

29 May 2016 at 15.30
Genomics in multiple myeloma
Dr. Norma Gutierrez, associate doctor in hematology, Hospital de Salamanca and lead researcher at the Institute for Biomedical Research of Salamanca (IBSAL)
Myeloma Group Dr. Albert Oriol

6 June 2016 at 15.30
Clinical and biological aspects of splenic marginal zone lymphoma
Dr. Estela Matutes. Hematopathology Unit Hospital Clinic, Barcelona.
Myeloma Group Dr. Albert Oriol

20 June 2016 at 15.30
MSC in myeloid malignancies
Dr. Thomas Schroeder. Medical Director of Radiation Oncology in UNM (Comprehensive Cancer Center)
Genetics and Epigenetics of Myeloid Neoplasms Dr. Lourdes Zamora

26 September 2016 at 15.30
MRD assessment in ALL: from PCR/flow to next generation sequencing
Dr. Monika Brüggemann. Department of Hematology. University Hospital Schleswig-Holstein
ALL Group Dr. Josep Mª Ribera

12 December 2016 at 15.30
The broad molecular and clinical spectrum of follicular lymphomas
Andreas Rosenwald. Professor of Pathology, Chairman. Institute of Pathology. University of Wuerzburg.
Lymphoid Neoplasms Dr. Tomás Navarro
Courses

Cytogenetics and Molecular Genetics of Myeloid Neoplasms.

Cytogenetics and Molecular Genetics of Myeloid Neoplasms.

Cytogenetics and Molecular Genetics of Myeloid Neoplasms.

Latest advances in acute lymphoblastic leukaemia.
Badalona, 8 and 9 September 2016.
Director: Josep Maria Ribera
IL3-UB. Madrid, 9 November 2016.
Speakers: Francesc Solé/Mar Mallo
Communication and congresses

- Special contributions at conferences: 26
- Oral communication (international): 9
- Oral communication (Spain): 18
- Posters (international): 7
- Posters (Spain): 6
Agreements

The IJC makes a great effort to establish continuing cooperation agreements, and it aims to broaden its strategic alliances and agreements with the pharmaceutical industry, as well as other private organisations. At the present time the following institutions are connected with the IJC:
Communication
Communication

The IJC knows that it is of prime importance to tell people about the work we do if we are to strengthen our bonds with society and its citizens. The desire to integrate social corporate responsibility into our management model is closely linked to the organisational values of the Josep Carreras Foundation.

To this end, the IJC has actively participated in scientific dissemination and in the creation of scientific vocations.

Rotary Club of Badalona

Children’s council visit
Tiana town council

Science week,
Badalona town council
Upcoming challenges
Upcoming challenges

Inauguration of the new building

In the autumn of 2017 the IJC will take a big step forward in the field of research into leukaemia with the inauguration of the new building in Badalona. The new building has 10,000m² of floor space, and it is the first European research centre to be exclusively focused on research into leukaemia and other malignant blood diseases. Furthermore, it has been accredited as a sustainable building on account of its reduced environmental impact, savings in energy consumption, reduction in maintenance costs and the increased satisfaction and wellbeing of the people who use it.

Strategic Plan 2018 – 2022

The Josep Carreras Leukaemia Research Institute has to have a very clear idea of its strategic horizon, and it has to have an organisational culture that is shared by everyone involved.

In 2017 the IJC starts out on a new phase and it will draw up the bases for a constructive and participative Strategic Plan that will be the road map setting out the answers to future challenges. The IJC has new challenges ahead and all the enthusiasm with which to face them together.

We are improving now to build tomorrow!
Annex
Scientific production 2016


Impact Factor: 1,267

Article
Impact Factor: 12,104

Article
Impact Factor: 4,510

Article
Impact Factor: 5,531

Article
Impact Factor: 5,008

Article
Impact Factor: 5,228

Article
Impact Factor: 4,316

Article
Impact Factor: 4,889


Impact Factor: 26,509


Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. NEW ENGL J MED 2016 Oct 6;375(14):1319-1331.

Impact Factor: 59,558


Impact Factor: 11,841


Impact Factor: 26,509


Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. BLOOD 2016 Nov 28. pii: blood-2016-08-733196. [Epub ahead of print]

Impact Factor: 11,841


Impact Factor: 1,267


Impact Factor: 1,053


Impact Factor: 3,979


Impact Factor: 12,104


Impact Factor: 3,257


Impact Factor: 2,544


Impact Factor: 9,269


Impact Factor: 1,267


GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study.


Article
Impact Factor: 3,636

doi: 10.1182/blood-2016-02-700054.
Article
Impact Factor: 11,841

Umbilical cord blood transplantation in adults with advanced hodgkin’s disease: high incidence of post-transplant lymphoproliferative disease.
Article
Impact Factor: 2,544

Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.
Article
Impact Factor: 8,556

Article
Impact Factor: 5,008

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Article
Impact Factor: 5,401

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Article
Impact Factor: 5,008


94 Sorigue M, Ribera JM, Motlló C, Sancho JM. New drugs for follicular lymphoma. 
Impact Factor: 2,606

95 Sorigue M, Ribera JM, Sancho JM. 
The clinical dilemma of grade 3 follicular lymphoma. 
Impact Factor: 9,269

96 Sorigue M, Sancho JM, García O, Vila J, Moreno M, Ribera JM. 
[Mantle cell lymphoma, response to treatment and prognosis in 45 patients]. 
English Abstract Impact Factor: 1,267

97 Sorigue M, Sancho JM, Ribera JM. 
Open questions in watchful waiting for follicular lymphoma. 
Impact Factor: 5,401

98 Stewart AK, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, 
P, Palumbo A. 
Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating 
Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With 
Relapsed Multiple Myeloma. 
Impact Factor: 20,982

99 Vazquez E, Mangues R, Villaverde A. 
Functional recruitment for drug delivery through protein-based nanotechnologies. NANOMEDICINE-UK 2016 
Impact Factor: 4,889
Headquarters
C/ Muntaner, 383 3r. 08021
Barcelona
Tel. (+34) 93 414 55 66

For any matter concerning this report please contact:
comunicacio@carrerasresearch.org
The report can also be downloaded from: http://www.carrerasresearch.org

Publisher, layout and typesetting
Josep Carreras Leukaemia Research Institute

Photography
Photographic archives of the Josep Carreras Leukaemia Foundation and the Josep Carreras Leukaemia Research Institute